Issue №041 · 2026-06-24

Daily Briefing · Issue №041 · 2026-06-24

Pharmacy

Why a deviation investigation still takes two weeks in the age of AI

  • Most of those two weeks is not science. It is finding and assembling the data, which is also where most of the AI sold to pharma quietly stalls.
Fierce Pharma ↗
Pharmacy

In another reversal for rare disease field, FDA to reconsider Regenxbio gene therapy

  • In another sign that the FDA is easing its stance toward rare disease drug candidates under new leadership, the agency will reconsider Regenxbio’s gene therapy for an ultra-rare childhood disease, a reversal coming just
FierceBiotech ↗
Pharmacy

Sanofi, Pangaea ink AI partnership deal to detect underdiagnosed genetic disease

  • French biopharma Sanofi inked a partnership deal with Pangaea Data to use its AI platform that helps detect Alpha-1 Antitrypsin Deficiency (AATD) that will be distributed to select healthcare systems and low-income commu
FierceBiotech ↗
Health OS

Prosper AI lands $30M backed by Andreessen Horowitz to build AI workforce for healthcare operations

  • Prosper AI banked $30 million to scale its agentic AI platform to power administrative tasks from patient scheduling to insurance verification and patient billing.
Fierce Healthcare ↗
Smillin.

A daily 5-minute brief on AI, devices, and digital tools across physicians, dentistry, pharmacy, physician assistants, nursing, digital health, and Health OS. Read by clinicians.

Smillin

Connect

© 2026 Smillin Healthcare TechTermsPrivacyUSA · Daily 6 AM ET